Suppr超能文献

在Deposiston治疗前及治疗期间,对患有遗传性高身材且分泌人生长激素的女孩持续静脉输注胰岛素(作者译)

[Continuous intravenous infusion of insulin to girls with hereditary tall growth and secretion of human growth hormone, prior to and during Deposiston treatment (author's transl)].

作者信息

Richter J, Heine W, Rudolf K, Uhlmann M

出版信息

Zentralbl Gynakol. 1980;102(19):1117-20.

PMID:7008461
Abstract

Continuous intravenous insulin infusion tests, accompanied by growth hormone determination, were applied to 40 girls of tall growth whose final lengths were predicted to be in excess of 181 cm. The girls were aged between nine and half and 14 years and one month, all of them being in the premenarchic phase. The tests were conducted prior to and following at least one year of Deposiston therapy (oestrogen/gestagen). - Really effective inhibition of growth (7.4 +/- 0.6 cm) was obtained only from five girls, aged between nine years and ten months and eleven years, in whom basal secretion of HGH was lower with significance than that of the whole group, with their stimulation reaction being fully retained. Secretion of somatotropic hormone (STH) of the other girls remained unaffected, prior to and following treatment. The weekly oestrogen dose of 1 mg was relatively low, when compared to propositions made by other authors, but it seemed to be justified by the average reduction in expected final body length obtained for the probands reviewed (5.4 +/- 2.0 cm).

摘要

对40名预计最终身高超过181厘米的高个子女孩进行了持续静脉输注胰岛素测试,并同时测定生长激素。这些女孩年龄在9岁半至14岁1个月之间,均处于月经初潮前阶段。测试在至少一年的Deposiston疗法(雌激素/孕激素)之前和之后进行。 - 仅在5名年龄在9岁10个月至11岁之间的女孩中获得了真正有效的生长抑制(7.4±0.6厘米),这些女孩的生长激素基础分泌显著低于整个组,但其刺激反应完全保留。其他女孩的生长激素分泌在治疗前后均未受到影响。与其他作者提出的建议相比,每周1毫克的雌激素剂量相对较低,但对于所研究的先证者预期最终身长的平均降低(5.4±2.0厘米)而言,这似乎是合理的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验